🇺🇸 FDA
Pipeline program

CTX131

CRSP-ONC-008

Phase 2 mab completed

Quick answer

CTX131 for T Cell Lymphoma is a Phase 2 program (mab) at CRISPR Therapeutics AG with 1 ClinicalTrials.gov record(s).

Program details

Company
CRISPR Therapeutics AG
Indication
T Cell Lymphoma
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials